COVID-19. COVID -19, virus identified
Conditions
Interventions
Intervention 1: Patients in the intervention group receive one Daclatasvir / Sofosbuvir 60/400 mg tablet (Danesh Pharmaceutical Development Company) daily for 7 days. Intervention 2: Control group: Re
Sponsors
Ahvaz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Age over 18 years old Respiratory rate more than 30 per minute Oxygen saturation less than 93% Confirmation of pneumonia by diagnostic CT scan of the chest
Exclusion criteria
Exclusion criteria: Taking the drug Amiodarone Kidney failure
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Respiratory rate. Timepoint: 14th day. Method of measurement: physical exam.;Arterial oxygen. Timepoint: 7th day. Method of measurement: Physical examination.;Requires mechanical ventilation. Timepoint: 7th day. Method of measurement: Physical examination.;Death. Timepoint: 7th day. Method of measurement: Physical examination.;Chest changes. Timepoint: 7th day. Method of measurement: Physical examination. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary consequences include the need for mechanical ventilation, chest changes (day 14 or earlier as determined by the physician), serious accidents, and mortality. Timepoint: 14th day. Method of measurement: Physical examination. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Zahrz Fakhrae
Ahvaz University of Medical Sciences
Outcome results
None listed